Recombinant Human Claudin-3 (CLDN3)

What is Claudin-3 and what is its role in cellular physiology?

Claudin-3 (CLDN3) is a 23 kDa multipass membrane protein belonging to the claudin family, which forms the backbone of epithelial tight junctions (TJs). As a critical structural component, CLDN3 contains four transmembrane domains and plays an essential role in maintaining epithelial barrier integrity. CLDN3 regulates paracellular permeability and maintains cell polarity in various epithelial tissues throughout the body .

From a structural perspective, human CLDN3 spans from Met1 to Val220 and functions through direct interactions with other claudin family members, particularly claudin-1 and claudin-5, to form the intricate network of tight junction strands. This network essentially creates a selective barrier controlling the passage of ions and molecules between epithelial cells .

Unlike many other claudin family members with tissue-specific expression patterns, CLDN3 is widely expressed across multiple epithelial tissues, making it a crucial target for various research applications in cellular biology, cancer research, and drug delivery studies.

How does recombinant CLDN3 differ from native CLDN3 in experimental applications?

Recombinant CLDN3 offers several advantages over native CLDN3 for experimental applications, though researchers should consider the following methodological distinctions:

• Structural consistency: Recombinant CLDN3 typically provides better experimental reproducibility than native protein extractions, as the amino acid sequence and post-translational modifications can be standardized across experiments.

• Expression systems: Most recombinant CLDN3 is produced using mammalian expression systems (particularly CHO cells) to ensure proper folding and post-translational modifications . When working with recombinant CLDN3, researchers should verify whether the expression system mimics the natural conformation, especially considering that CLDN3 antibody binding often depends on recognizing the native conformation .

• Experimental constraints: Native CLDN3 maintains its natural interactions with other tight junction proteins, whereas recombinant systems may lack these associated proteins unless specifically co-expressed. This distinction becomes particularly important when studying CLDN3's functional role in barrier formation rather than just protein-protein interactions.

For optimal experimental design, researchers should select stable cell lines expressing human CLDN3, such as recombinant Claudin-3 CHO K1 cell lines, which have been verified for surface expression using flow cytometry and selected for high-level expression compared to parental CHO K1 cells .

What factors regulate CLDN3 expression in normal and pathological conditions?

CLDN3 expression is regulated by multiple factors in both physiological and pathological states:

Growth Factors and Cytokines:

• Epidermal Growth Factor (EGF) significantly upregulates CLDN3 expression

• Inflammatory mediators increase CLDN3 expression during acute and chronic inflammatory responses

Pathological Conditions:

• CLDN3 expression is significantly reduced in lung squamous cell carcinoma tissues compared to adjacent normal tissues

• Blood-brain barrier disruption is associated with loss of CLDN3 expression, suggesting its role in maintaining central nervous system compartmentalization

• Wnt/β-catenin signaling pathway activation can modulate CLDN3 expression, with implications for epithelial-mesenchymal transition (EMT) in cancer progression

Experimental Approaches for Studying CLDN3 Regulation:
To investigate CLDN3 regulation, researchers typically employ quantitative real-time PCR (qRT-PCR) and western blot analysis to measure expression levels in paired tissue samples (e.g., cancer vs. adjacent normal tissue) . For mechanistic studies, ectopic CLDN3 overexpression or knockdown can be generated using plasmids carrying CLDN3 cDNA or shRNA, respectively, with subsequent analysis of downstream signaling pathways.

How can researchers establish reliable stable CLDN3-expressing cell lines for long-term studies?

Establishing stable CLDN3-expressing cell lines requires careful consideration of the following methodological approaches:

Step-by-Step Protocol:

• Clone CLDN3 cDNA into an appropriate expression vector (e.g., pcDNA3.1(+))

• Transfect the construct into desired cell lines (e.g., CHO-K1, L cells, HEK293, or TOV-112D cells) using an efficient transfection reagent like FuGENE HD

• Select G418-resistant cells after transfection

• Isolate individual clones using a clonal cylinder

• Verify CLDN3 expression through western blot and flow cytometry

Cell Line Selection Considerations:
For optimal results, researchers should select a host cell line with minimal endogenous CLDN3 expression. For cancer studies, the cell background should match the cancer type of interest - for instance, using lung cancer cell lines H520 or SK-MES-1 for lung cancer research, or ovarian cancer cell lines for studying CLDN3's role in ovarian malignancies .

Expression Verification:
Surface expression of CLDN3 should be confirmed using flow cytometry, comparing expression levels to parental cells to ensure significant upregulation. For antibody development or binding studies, cell-based affinity kinetics can be measured using systems like LigandTracer Green with Dylight dye 488-labeled antibodies .

How does CLDN3 expression affect cancer progression and metastasis?

CLDN3 exhibits context-dependent roles in cancer progression that vary by cancer type:

Lung Squamous Cell Carcinoma (SqCC):
CLDN3 functions as a tumor suppressor in lung SqCC, with significant experimental evidence indicating:

• CLDN3 expression is markedly reduced in lung SqCC tissues compared to adjacent normal tissues

• Ectopic CLDN3 overexpression inhibits migration, invasion, and epithelial-mesenchymal transition (EMT) of lung cancer H520 cells

• Conversely, CLDN3 knockdown promotes these malignant phenotypes in SK-MES-1 cells

• Importantly, CLDN3 modulation does not affect cell proliferation or colony formation, suggesting its specific role in metastatic processes rather than tumor growth

Ovarian Cancer:
In contrast to its suppressive role in lung SqCC, CLDN3 is frequently overexpressed in ovarian cancer, potentially contributing to disease progression .

Colon Cancer:
CLDN3 depletion increases tumor burden by enhancing β-catenin activity through IL-6/STAT3 signaling, indicating a tumor-suppressive role in colorectal malignancies .

Mechanistic Insights:
The anti-metastatic effects of CLDN3 in lung SqCC correlate with regulation of EMT biomarkers:

• CLDN3 expression positively correlates with E-cadherin (epithelial marker)

• CLDN3 expression inversely correlates with Vimentin (mesenchymal marker)

• CLDN3 modulates these EMT markers through regulation of the Wnt/β-catenin signaling pathway

This differential expression and function across cancer types highlights the importance of tissue-specific context when studying CLDN3's role in cancer.

What experimental approaches can researchers use to study CLDN3-mediated epithelial-mesenchymal transition (EMT) in cancer cells?

To investigate CLDN3's role in EMT, researchers can employ several methodological approaches:

Gene Expression Modulation:

• Overexpression Systems: Transfect cancer cells with CLDN3 cDNA using appropriate vectors and evaluate EMT marker expression and cellular phenotypes

• Knockdown Approaches: Use shRNA (e.g., sequence 5ʹ-ACCGCAAGGACTACGTCTA-3ʹ) delivered via lentiviral vectors to reduce CLDN3 expression

• Validation: Confirm successful expression modulation via western blot and/or qRT-PCR

EMT Assessment Techniques:

• Migration and Invasion Assays: Transwell migration assays and Matrigel invasion assays to quantify cellular motility

• EMT Marker Analysis: Western blot and immunofluorescence to evaluate expression of:

  • E-cadherin (epithelial marker)

  • Vimentin (mesenchymal marker)

  • Additional EMT-related transcription factors (Snail, Slug, ZEB1/2)

• Signaling Pathway Analysis: Examine Wnt/β-catenin pathway components, as CLDN3 modulates EMT through this signaling cascade

Advanced Analysis Methods:
For mechanistic insights, researchers should consider analyzing the relationship between CLDN3 and the Wnt/β-catenin pathway through:

• TOPFlash/FOPFlash reporter assays to measure β-catenin transcriptional activity

• Co-immunoprecipitation to identify CLDN3 protein interactions

• Immunofluorescence to assess β-catenin nuclear localization

• Pharmacological manipulation using Wnt pathway activators or inhibitors to confirm pathway involvement

These approaches enable comprehensive characterization of how CLDN3 modulates EMT processes in cancer progression.

What are the challenges and solutions for developing specific antibodies against CLDN3?

Developing specific antibodies against CLDN3 presents several significant challenges:

Key Challenges:

• Structural Complexity: CLDN3 is a four-transmembrane domain protein with limited exposed extracellular loops, providing minimal antigenic regions

• High Homology: Significant sequence similarity exists among claudin family members and across species (human CLDN3 shares 91% amino acid sequence identity with mouse and rat CLDN3)

• Native Conformation Recognition: Many applications require antibodies that recognize the native conformation of CLDN3 rather than denatured forms

Methodological Solutions:
Researchers have successfully addressed these challenges through:

• Advanced Immunization Strategies:

  • Using CLDN3-overexpressing stable cells as immunogens to present the protein in its native conformation

  • Employing CLDN3-embedded lipoparticles as antigens to mimic membrane presentation

• Sophisticated Screening Methods:

  • Implementing scFv phage display technology to isolate high-affinity binders

  • Performing extensive cross-reactivity testing against other claudin family members

  • Confirming specificity using both positive (CLDN3-expressing) and negative control cell lines

• Validation Approaches:

  • Flow cytometry to confirm binding to natively expressed CLDN3

  • Cell-based affinity kinetics measurements using systems like LigandTracer Green

  • Testing across multiple cell lines expressing human and mouse CLDN3 to confirm species cross-reactivity

Using these approaches, researchers have successfully developed antibodies like the human IgG1 monoclonal antibody (h4G3) that recognizes the native conformation of both human and mouse CLDN3 with sub-nanomolar affinity and without cross-reactivity to other claudins .

What methods are most effective for detecting and quantifying CLDN3 expression in experimental settings?

Multiple complementary approaches can be used to effectively detect and quantify CLDN3 expression:

Protein-Level Detection Methods:

• Flow Cytometry:

  • Optimal for detecting cell surface CLDN3 expression

  • Example protocol: Stain cells with anti-CLDN3 PE-conjugated monoclonal antibody (e.g., Catalog # FAB4620P) and compare to isotype control antibody (e.g., Catalog # IC003P)

  • Provides quantitative assessment of protein expression levels on a per-cell basis

• Western Blotting:

  • Effective for total CLDN3 protein quantification

  • Confirms protein size (approximately 23 kDa)

  • Useful for comparing expression between experimental conditions or tissue samples

• Immunofluorescence Microscopy:

  • Visualizes CLDN3 localization within cells

  • Critical for confirming tight junction localization

  • Can be combined with other tight junction markers for co-localization studies

Transcript-Level Detection:

• Quantitative Real-Time PCR (qRT-PCR):

  • Measures CLDN3 mRNA expression levels

  • Useful for high-throughput screening across multiple samples

  • Complements protein-level detection methods

Advanced Quantitative Approaches:

For optimal results, researchers should employ multiple detection methods in parallel, as each provides complementary information about CLDN3 expression, localization, and function.

How can CLDN3 be targeted for therapeutic purposes in cancer and other diseases?

CLDN3's distinctive expression patterns and functional roles offer several strategic approaches for therapeutic targeting:

Cancer-Directed Therapies:

• Antibody-Based Approaches:

  • Develop highly specific monoclonal antibodies against CLDN3's extracellular domains

  • Human IgG1 monoclonal antibodies like h4G3 with sub-nanomolar affinity for CLDN3 show promise as potential therapeutic agents

  • These antibodies can potentially be developed into antibody-drug conjugates (ADCs) for targeted delivery of cytotoxic agents to CLDN3-overexpressing cancer cells

• Claudin-Targeted Toxins:

  • Exploit CLDN3's natural role as a receptor for Clostridium perfringens enterotoxin (CPE)

  • CPE binding to CLDN3 induces epithelial cell lysis, offering a natural cytotoxic mechanism

  • Modified CPE-based therapeutics could selectively target CLDN3-overexpressing cancer cells, particularly in ovarian cancers where CLDN3 is frequently upregulated

• Signaling Pathway Modulation:

  • For cancers where CLDN3 is downregulated (e.g., lung SqCC), therapeutic strategies could aim to restore CLDN3 expression

  • This might be achieved through inhibition of the Wnt/β-catenin pathway, which appears to regulate CLDN3-mediated EMT

Methodological Considerations for Therapeutic Development:

• Target Validation:

  • Confirm differential expression between normal and diseased tissues

  • Verify accessibility of the target in vivo using imaging studies with labeled antibodies

• Therapeutic Efficacy Screening:

  • Establish appropriate cell line models expressing varying levels of CLDN3

  • Develop xenograft models to evaluate in vivo efficacy

  • Consider using stable CLDN3-expressing cell lines (e.g., Claudin-3 CHO cell lines) for initial screening

• Specificity Assessment:

  • Evaluate cross-reactivity with other claudin family members, particularly CLDN4 which shares structural similarities with CLDN3

  • Test effects on normal tissues expressing physiological levels of CLDN3

The development of CLDN3-targeted therapeutics represents a promising approach, particularly for epithelial cancers with altered CLDN3 expression.

What role does CLDN3 play in regulating the blood-brain barrier, and how can this be studied experimentally?

CLDN3 serves as a critical regulator of blood-brain barrier (BBB) integrity, with important implications for neurological disorders and drug delivery:

Functional Role in BBB:

• CLDN3 is expressed in the tight junctions of brain endothelial cells, contributing to the selective permeability of the BBB

• Its expression is notably lost during pathological disruptions of the BBB structure

• This downregulation may contribute to increased vascular permeability in various neurological conditions

Experimental Approaches for BBB Research:

• In Vitro BBB Models:

  • Develop transwell culture systems using brain endothelial cells expressing CLDN3

  • Measure transendothelial electrical resistance (TEER) to quantify barrier function

  • Assess permeability using fluorescently labeled dextrans or other tracer molecules

  • Manipulate CLDN3 expression through overexpression or knockdown to establish causative relationships

• CLDN3 Expression Analysis in BBB Disruption:

  • Compare CLDN3 levels between healthy and pathological brain tissue samples

  • Correlate CLDN3 expression with BBB permeability markers

  • Investigate regulatory mechanisms controlling CLDN3 downregulation during BBB disruption

• Animal Models for BBB Studies:

  • Develop conditional CLDN3 knockout mice specific to brain endothelial cells

  • Use cranial window techniques combined with intravital microscopy to visualize BBB function in real-time

  • Employ models of neuroinflammation, stroke, or traumatic brain injury to study pathological BBB disruption

• Therapeutic Applications:

  • Investigate approaches to stabilize or upregulate CLDN3 expression during BBB disruption

  • Explore targeted drug delivery strategies that leverage CLDN3 expression patterns

  • Develop imaging agents that bind to CLDN3 for non-invasive assessment of BBB integrity

Understanding CLDN3's role in BBB regulation offers significant potential for developing new therapeutic strategies for neurological disorders characterized by BBB dysfunction, as well as improved methods for drug delivery across this challenging biological barrier.

What are common technical challenges when working with recombinant CLDN3 and how can they be addressed?

Researchers frequently encounter several technical challenges when working with recombinant CLDN3, which can be addressed through specific methodological refinements:

Challenge 1: Protein Misfolding and Aggregation

• Problem: As a transmembrane protein, CLDN3 may misfold or aggregate when expressed recombinantly

• Solution:

  • Use mammalian expression systems (particularly CHO cells) rather than bacterial systems

  • Include mild detergents during protein extraction and purification

  • Consider co-expression with chaperone proteins to facilitate proper folding

  • Optimize cell culture conditions, including temperature reduction during expression phase

Challenge 2: Low Surface Expression

• Problem: Recombinant CLDN3 may not efficiently traffic to the cell surface

• Solution:

  • Verify surface expression using flow cytometry with non-permeabilized cells

  • Select stable clones with confirmed high surface expression levels

  • Consider adding trafficking signal sequences to expression constructs

  • Screen multiple cell lines to identify optimal expression systems

Challenge 3: Antibody Recognition Issues

• Problem: Antibodies may fail to recognize native conformation of CLDN3

• Solution:

  • Use antibodies specifically developed against native CLDN3 conformation

  • Employ alternative detection methods for verification (e.g., tagged CLDN3 constructs)

  • Consider using CLDN3-embedded lipoparticles as antigens for antibody development

  • Validate antibody binding through multiple methodologies (western blot, flow cytometry, immunofluorescence)

Challenge 4: Functional Assessment Difficulties

• Problem: Determining if recombinant CLDN3 maintains physiological functions

• Solution:

  • Establish barrier function assays (transepithelial/endothelial electrical resistance)

  • Confirm proper localization to tight junctions through co-localization with other tight junction proteins

  • Verify interaction with known binding partners (claudin-1, claudin-5) through co-immunoprecipitation

  • Test susceptibility to Clostridium perfringens enterotoxin as a functional readout

Implementing these technical solutions can significantly improve the reliability and reproducibility of experiments involving recombinant CLDN3.

How can researchers effectively design experiments to investigate the relationship between CLDN3 and the Wnt/β-catenin signaling pathway?

The interaction between CLDN3 and the Wnt/β-catenin signaling pathway represents a critical research area, particularly in cancer studies. Here is a methodological framework for designing rigorous experiments to investigate this relationship:

Experimental Design Strategy:

• Expression Correlation Analysis:

  • Assess correlation between CLDN3 expression and key Wnt pathway components (β-catenin, GSK-3β, Axin) in tissue samples and cell lines

  • Use multivariate analysis to account for confounding factors

  • Employ both transcriptomic (qRT-PCR) and proteomic (western blot) approaches

• Manipulation of CLDN3 Expression:

  • Establish gain-of-function models through CLDN3 overexpression using lentiviral vectors

  • Create loss-of-function models using CLDN3-specific shRNA (e.g., sequence 5ʹ-ACCGCAAGGACTACGTCTA-3ʹ)

  • Compare effects on Wnt pathway activation in both models

• Wnt Pathway Activity Assessment:

  • Measure β-catenin nuclear translocation through cellular fractionation and immunofluorescence

  • Employ TOPFlash/FOPFlash reporter assays to quantify β-catenin-mediated transcriptional activity

  • Assess expression of downstream Wnt target genes (c-Myc, Cyclin D1, Axin2) via qRT-PCR

• Mechanistic Interventions:

  • Use Wnt pathway activators (e.g., CHIR99021, Wnt3a) and inhibitors (e.g., XAV939, IWR-1) to determine if they can rescue or reverse CLDN3-mediated effects

  • Employ domain-specific CLDN3 mutants to identify regions responsible for Wnt pathway interaction

  • Consider using chimeric ECL fusion constructs (as described in ) to pinpoint interaction domains

• In Vivo Validation:

  • Develop xenograft models with CLDN3-overexpressing or CLDN3-knockdown cells

  • Analyze tumor growth, EMT marker expression, and Wnt pathway activation in vivo

  • Consider genetic mouse models with conditional CLDN3 alterations for more physiologically relevant studies

This comprehensive experimental framework enables researchers to establish not just correlative but causal relationships between CLDN3 and the Wnt/β-catenin pathway, providing insights into potential therapeutic approaches targeting this interaction in diseases like lung squamous cell carcinoma where CLDN3 appears to suppress metastasis through Wnt pathway modulation .